查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2017704

自體免疫疾病治療市場：2026-2032年全球市場預測（按治療方法、疾病、給藥途徑、治療應用和最終用戶分類）

Autoimmune Disease Therapeutics Market by Therapeutic Types, Disease Type, Route of Administration, Therapeutic Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，自體免疫疾病治療市場價值將達到 1,897.7 億美元，到 2026 年將成長至 2,095.3 億美元，到 2032 年將達到 3,823.3 億美元，複合年成長率為 10.52%。

主要市場統計數據
基準年 2025 1897.7億美元
預計年份：2026年 2095.3億美元
預測年份 2032 3823.3億美元
複合年成長率 (%) 10.52%

簡明策略介紹，概述自體免疫療法市場的臨床挑戰、商業性現實和相關人員合作。

自體免疫疾病治療領域的特點是科學進展迅速、監管流程複雜以及支付方期望不斷變化，這些因素共同影響研發者和投資者的策略選擇。在此背景下，經營團隊需要一份簡明扼要的概述，將臨床挑戰與商業性現實相結合，以便更好地制定研發管線優先級、分配資金並與外部合作夥伴開展合作。

科學、商業性和營運創新如何融合，從而重塑自體免疫疾病治療的臨床策略和商業化路徑。

科學、技術和政策的變革性轉變正在重新定義自體免疫疾病的診斷、治療和管理方式，其影響波及整個價值鏈。生物製藥的進步、針對小分子化合物的改進以及精準免疫調節方法的成熟，使得治療策略能夠更加明確地著眼於改變疾病進展和實現持續緩解，而不僅僅是控制症狀。

本研究評估了不斷變化的關稅政策如何影響自體免疫療法供應鏈的韌性、製造地的決策以及籌資策略。

美國將於2025年實施新的關稅措施及相關貿易調整，將對自體免疫療法的供應鏈、成本結構和產業計畫產生多方面的影響。這些措施不僅會影響活性藥物成分和生物製藥原料的上游採購，還會影響下游決策，例如最終組裝、填充和包裝流程的選址以及低溫運輸物流設施。因此，各公司正在重新審視其籌資策略，以在維持供應連續性的同時，盡可能降低進口成本飆升的影響。

將治療方法、適應症、給藥途徑、治療目標和臨床環境與開發和商業化要求聯繫起來的綜合細分分析。

一套精細的細分框架揭示了治療方式、適應症、給藥途徑、治療目標和最終用戶環境如何決定研發重點和商業化策略。治療類型涵蓋多種療法，例如生技藥品（包括降血糖藥物、融合蛋白、基因治療方法和單株抗體）、細胞激素抑制劑、免疫調節劑、免疫抑制劑、非類固醇消炎劑、磷酸二酯酶抑制劑以及小分子化合物（包括皮質類固醇和JAK抑制劑）。每類藥物都面臨獨特的研發挑戰、監管證據要求和生產方面的考量，這些都會影響臨床試驗時間和價值主張。

美洲、歐洲、中東、非洲和亞太地區由於管理體制、支付模式和臨床實踐模式的差異而產生的區域策略影響。

區域趨勢在策略規劃中至關重要，因為監管要求、支付方結構和臨床實踐模式因地區而異。在美洲，重點在於基於價值的報銷途徑、突破性治療方法的加速核准項目，以及影響產品上市順序和合約策略的廣泛專科藥房和綜合醫療保健網路。在這種環境下，健全的真實世界數據項目和早期與支付方的合作對於確保藥物可及性和報銷結果至關重要。

透過科學創新、製造管理和證據生成能力相結合而脫穎而出的關鍵競爭和夥伴關係趨勢。

領先的研發公司、契約製造組織 (CMO) 和服務供應商之間的競爭動態日益受到策略聯盟、垂直整合和有針對性的收購的影響，這些舉措旨在擴大生產規模和提昇科研能力。擁有深厚生物製劑專業知識和單株抗體、融合蛋白和基因療法專有平台的公司，正透過將臨床差異化與生產控制相結合，尋求獨特的市場定位，從而降低上市風險並提高品質保證。同時，小規模、更靈活的創新公司則利用夥伴關係開發特化分子和針對特定適應症的藥物，通常專注於伴隨診斷和患者分層。

切實可行的策略建議，旨在協調臨床開發、供應鏈韌性和市場准入準備，以加快患者獲得治療和商業性成功。

產業領導企業應優先採取一系列切實可行的措施來應對三大挑戰：臨床差異化、供應鏈韌性和市場準備。首先，早期臨床開發應與支付方的證據要求保持一致，並積極與監管機構合作，以降低與III期臨床試驗設計和終點選擇相關的風險。投資於基於生物標記的患者分層和適應性調查方法可以縮短開發週期，並加強價值提案的論點。其次，供應商網路應多元化，並探索區域性生產和策略夥伴關係關係，以降低關稅和物流波動風險，同時在臨床和商業化階段維持品質合規性和穩定的供應。

一種透明、多方面的調查方法，結合了專家訪談、監管分析、科學文獻綜述和供應鏈情境評估。

本研究採用多方面方法，結合定性專家訪談、監管和政策分析以及同行評審的科學文獻，為策略決策建立了可靠的證據基礎。關鍵的定性資料是透過對臨床研究人員、供應鏈高管、市場進入專家和支付方代表的結構化訪談收集的，從而能夠從多個觀點從研發到商業化的整個流程。

結論將臨床潛力與營運要求和市場進入先決條件相結合，以實現對患者產生有意義的影響。

總之，自體免疫疾病治療領域正處於轉折點，需要在科學突破、嚴謹的實踐應用和成熟的市場進入策略之間取得平衡。先進生物製藥、標靶小分子化合物和精準醫療方法的融合為改變疾病進程提供了重要機遇，但要實現這一潛力，需要累積臨床證據、確保生產可靠性以及與支付方持續合作。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療類型分類的自體免疫疾病治療市場

  • 降血糖藥物
  • 生物製藥
    • 融合蛋白
    • 基因治療
    • 單株抗體
  • 細胞激素抑制劑
  • 免疫調節劑
  • 免疫抑制劑
  • 非類固醇消炎劑（NSAIDs）
  • 磷酸二酯酶抑制劑
  • 低分子化合物
    • 皮質類固醇
    • JAK抑制劑

第9章：自體免疫疾病治療市場：依疾病類型分類

  • 發炎性腸道疾病
  • 全身性紅斑性狼瘡
  • 多發性硬化症
  • 銀屑病
  • 類風濕性關節炎
  • 1型糖尿病

第10章：自體免疫疾病治療市場：依給藥途徑分類

  • 注射藥物
    • 肌肉內部
    • 靜脈
    • 皮下
  • 口服

第11章：按治療應用分類的自體免疫疾病治療市場

  • 抑制疾病進展
  • 免疫系統調節
  • 疼痛管理
  • 減輕發炎

第12章：自體免疫疾病治療市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 研究機構

第13章：自體免疫疾病治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：自體免疫疾病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：自體免疫疾病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國自體免疫疾病治療市場

第17章：中國自體免疫疾病治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs, LLC
  • bioMerieux SA
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Exagen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • UCB SA
  • Werfen SA
Product Code: MRR-030C42D3EDB7

The Autoimmune Disease Therapeutics Market was valued at USD 189.77 billion in 2025 and is projected to grow to USD 209.53 billion in 2026, with a CAGR of 10.52%, reaching USD 382.33 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 189.77 billion
Estimated Year [2026] USD 209.53 billion
Forecast Year [2032] USD 382.33 billion
CAGR (%) 10.52%

A concise strategic introduction framing clinical imperatives, commercial realities, and stakeholder alignment across the autoimmune therapeutics landscape

The autoimmune therapeutics landscape is characterized by rapid scientific progress, complex regulatory pathways, and evolving payer expectations that together shape strategic choices for developers and investors. In this environment, a concise introduction that harmonizes the clinical imperatives with commercial realities is essential for executive teams preparing to prioritize pipelines, allocate capital, and engage external partners.

This section sets the stage by outlining prevailing clinical unmet needs, the accelerating role of precision biologics and small molecule agents, and the operational challenges associated with manufacturing, cold chain logistics, and real-world evidence generation. It emphasizes the interplay between clinical trial design and long-term value creation, and it underscores the importance of early alignment with key stakeholders, including clinicians, payers, and specialty pharmacies. Transitional insights highlight where near-term innovations are likely to intersect with systemic constraints, providing a pragmatic foundation for the deeper analyses that follow

How scientific, commercial, and operational innovations converge to reshape clinical strategies and commercialization pathways in autoimmune disease treatment

Transformative shifts across science, technology, and policy are redefining how autoimmune diseases are diagnosed, treated, and managed, with implications that reverberate across the entire value chain. Advances in biologic modalities, improvements in targeted small molecule chemotypes, and maturation of precision immunomodulatory approaches are enabling therapeutic strategies that focus more explicitly on altering disease progression and achieving durable remission rather than merely managing symptoms.

Concurrently, diagnostic improvements and biomarker-driven patient segmentation are reshaping clinical trial cohorts and accelerating adaptive trial designs. These scientific shifts are complemented by commercial and operational transformations, including increased vertical integration among developers, greater reliance on strategic partnerships for manufacturing and distribution, and elevated expectations for digital health adjuncts that improve adherence and monitor safety. Together, these changes necessitate a re-evaluation of traditional commercialization playbooks and call for integrated strategies that align clinical differentiation with scalable manufacturing and payer evidence requirements

Assessing how evolving tariff policies influence supply chain resilience, manufacturing footprint decisions, and procurement strategies for autoimmune therapies

The introduction of new tariff measures and related trade adjustments in the United States in 2025 exerts multifaceted effects across supply chains, cost structures, and operational planning for autoimmune therapeutics. These measures influence upstream procurement of active pharmaceutical ingredients and biologic raw materials, as well as downstream decisions related to where to site final assembly, fill-finish operations, and cold chain logistics. As a result, companies are recalibrating sourcing strategies to mitigate exposure to elevated import costs while preserving supply continuity.

In response, many stakeholders are pursuing near-shoring and regionalization strategies to reduce transit times and regulatory friction, which in turn changes lead times for clinical supplies and commercial inventory. Contract manufacturers and distributors are renegotiating terms to absorb operational complexity and to ensure service level continuity. From a strategic perspective, these dynamics emphasize the importance of supply chain resilience, diversified supplier networks, and scenario planning that integrates tariff sensitivity analyses into regulatory submission timelines and clinical development budgets. Ultimately, organizations that proactively adapt their sourcing and manufacturing footprints will be better positioned to maintain patient access and to protect therapeutic margins

Comprehensive segmentation analysis that links modality, indication, administration route, therapeutic intent, and care setting to development and commercialization imperatives

A nuanced segmentation framework reveals how therapeutic modality, disease indication, administration route, therapeutic intent, and end-user environment jointly inform development priorities and commercialization tactics. Therapeutic types encompass a diverse set of modalities including Antihyperglycemics, Biologics such as Fusion Proteins, Gene Therapy, and Monoclonal Antibodies, Cytokine Inhibitors, Immunomodulators, Immunosuppressants, Nonsteroidal Anti-Inflammatory Drugs, Phosphodiesterase Inhibitors, and Small Molecules which further include Corticosteroids and JAK Inhibitors. Each class carries distinct development challenges, regulatory evidence expectations, and manufacturing considerations that influence time-to-clinic and value narratives.

Disease types range across Inflammatory Bowel Disease, Lupus Erythematosus, Multiple Sclerosis, Psoriasis, Rheumatoid Arthritis, and Type 1 Diabetes, and this distribution of indications drives heterogeneity in endpoint selection, trial duration, and patient recruitment complexity. Route of administration considerations split primarily between Injectable and Oral therapies, with injectable delivery further differentiated by intramuscular, intravenous, and subcutaneous approaches; these factors have direct implications for patient preference, adherence patterns, and the types of support services required at launch. Therapeutic application objectives span disease progression alteration, immune system modulation, pain management, and reduction of inflammation, each demanding tailored clinical programs and differentiated messaging. End-user contexts include ambulatory surgical centers, hospitals, and research institutes, and these settings dictate procurement processes, formulary positioning, and the cadence of post-market evidence collection. By synthesizing these segmentation dimensions, developers can prioritize indications and modalities that align with internal capabilities and external access realities, while payers and providers can better anticipate which therapeutic profiles will offer the most compelling value propositions in distinct care settings

Regional strategic implications tied to divergent regulatory regimes, payer models, and clinical practice patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics are critical to strategic planning because regulatory requirements, payer architectures, and clinical practice patterns diverge substantially across geographies. In the Americas, there is a concentrated emphasis on value-based reimbursement pathways, accelerated regulatory programs for breakthrough therapies, and an extensive network of specialty pharmacies and integrated delivery networks that influence launch sequencing and contracting strategies. This environment rewards robust real-world evidence programs and early payer engagement to secure access and reimbursement outcomes.

Europe, Middle East & Africa presents a mosaic of market access approaches, with varying degrees of centralized assessment and country-specific pricing negotiations; here, alignment with health technology assessment expectations and local clinical guidelines is essential. The region often favors therapeutic approaches that demonstrate clear cost-offsets and long-term benefits. Asia-Pacific markets exhibit rapid adoption of innovative therapies in certain high-capacity health systems, while other countries within the region are characterized by constrained public budgets and tiered access strategies. For these markets, flexible pricing models, partnerships with local manufacturers, and tailored clinical development plans can accelerate uptake. Across all regions, cross-border regulatory harmonization efforts and evolving digital infrastructure will continue to influence strategic choices for clinical development and commercialization

Key competitive and partnership dynamics that deliver differentiation through combined scientific innovation, manufacturing control, and evidence generation capabilities

Competitive dynamics among lead developers, contract manufacturing organizations, and service providers are increasingly shaped by strategic collaborations, vertical integration, and targeted acquisitions that unlock manufacturing scale and scientific capabilities. Companies with deep biologics expertise and proprietary platforms for monoclonal antibodies, fusion proteins, and gene therapies are pursuing differentiated positioning by coupling clinical differentiation with manufacturing control, thereby reducing time-to-market risk and enhancing quality assurance. At the same time, smaller, nimble innovators are leveraging partnerships to advance specialized molecules and niche indications, often focusing on companion diagnostics and patient stratification.

Contract manufacturing and logistics providers that can demonstrate cold chain reliability, flexible capacity, and regulatory compliance are becoming de facto extension partners for developers seeking to minimize supply disruptions. Additionally, organizations that invest in robust real-world evidence generation and patient support programs enhance their negotiating posture with payers and providers. These strategic moves collectively favor entities that can align scientific novelty with operational excellence and payer-relevant evidence generation, creating a competitive advantage for those able to orchestrate end-to-end development and commercialization pathways

Actionable strategic recommendations that align clinical development, supply chain resilience, and market access preparations to accelerate patient access and commercial success

Industry leaders should prioritize a set of pragmatic, actionable steps that address clinical differentiation, supply chain resilience, and market access readiness. First, align early clinical development with payer evidence requirements and engage with regulatory authorities proactively to de-risk pivotal trial design and endpoint selection. Investing in biomarker-driven patient stratification and adaptive trial methodologies can shorten development cycles and strengthen value dossiers. Second, diversify supplier networks and consider regionalized manufacturing or strategic partnerships to mitigate tariff and logistics volatility while maintaining quality compliance and reliable supply for clinical and commercial phases.

Third, design integrated go-to-market strategies that couple clinical benefits with operational support services such as patient assistance, adherence programs, and digital health tools that improve outcomes and reduce total cost of care. Fourth, pursue deliberate collaborations with contract manufacturers, distribution partners, and clinical research organizations to secure capacity and specialized capabilities at critical inflection points. Finally, embed real-world evidence planning into development pathways to support reimbursement discussions across diverse regional systems. By sequencing these actions and tying them to clear milestones, leaders can reduce execution risk and accelerate patient access

Transparent multi-method research methodology combining expert interviews, regulatory analysis, scientific literature review, and supply chain scenario assessments

This research integrates a multi-method approach that combines qualitative expert interviews, regulatory and policy analysis, and synthesis of peer-reviewed scientific literature to produce a robust evidence base for strategic decision-making. Primary qualitative inputs were obtained through structured interviews with clinical investigators, supply chain executives, market access specialists, and payer representatives, enabling triangulation of perspectives across the development and commercialization continuum.

Secondary analysis consisted of a careful review of regulatory guidance, clinical trial registries, and scientific publications to validate modality-specific development pathways and safety profiles. Supply chain and tariff impact assessments were constructed using trade flow data and logistics benchmarks, together with scenario-based sensitivity checks to identify points of vulnerability. Throughout the methodology, cross-validation exercises ensured that conclusions were grounded in observable trends and expert judgment rather than speculation, and transparency around data sources and assumptions supports reproducibility and targeted follow-up analyses

Concluding perspective that synthesizes clinical promise with operational imperatives and market access prerequisites for meaningful patient impact

In conclusion, the autoimmune therapeutics arena is at an inflection point where scientific breakthroughs must be matched with disciplined operational execution and sophisticated market access strategies. The convergence of advanced biologics, targeted small molecules, and precision medicine approaches presents substantial opportunity to alter disease trajectories, but realizing that potential requires alignment across clinical evidence generation, manufacturing reliability, and payer engagement.

Leaders that invest in resilient supply chains, biomarker-enabled development, and integrated commercial support services will be best positioned to transform therapeutic promise into sustainable patient impact. As regulatory and trade landscapes evolve, continuous scenario planning and proactive stakeholder alignment will serve as the differentiating factors between programs that achieve broad access and those that face protracted adoption hurdles

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Autoimmune Disease Therapeutics Market, by Therapeutic Types

  • 8.1. Antihyperglycemics
  • 8.2. Biologics
    • 8.2.1. Fusion Proteins
    • 8.2.2. Gene Therapy
    • 8.2.3. Monoclonal Antibodies
  • 8.3. Cytokine Inhibitors
  • 8.4. Immunomodulators
  • 8.5. Immunosuppressants
  • 8.6. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 8.7. Phosphodiesterase Inhibitors
  • 8.8. Small Molecules
    • 8.8.1. Corticosteroids
    • 8.8.2. JAK Inhibitors

9. Autoimmune Disease Therapeutics Market, by Disease Type

  • 9.1. Inflammatory Bowel Disease
  • 9.2. Lupus Erythematosus
  • 9.3. Multiple Sclerosis
  • 9.4. Psoriasis
  • 9.5. Rheumatoid Arthritis
  • 9.6. Type 1 Diabetes

10. Autoimmune Disease Therapeutics Market, by Route of Administration

  • 10.1. Injectable
    • 10.1.1. Intramuscular
    • 10.1.2. Intravenous
    • 10.1.3. Subcutaneous
  • 10.2. Oral

11. Autoimmune Disease Therapeutics Market, by Therapeutic Application

  • 11.1. Disease Progression Alteration
  • 11.2. Immune System Modulation
  • 11.3. Pain Management
  • 11.4. Reduction of Inflammation

12. Autoimmune Disease Therapeutics Market, by End-User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Research Institutes

13. Autoimmune Disease Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Autoimmune Disease Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Autoimmune Disease Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Autoimmune Disease Therapeutics Market

17. China Autoimmune Disease Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AbbVie Inc.
  • 18.7. Amgen Inc.
  • 18.8. AstraZeneca PLC
  • 18.9. Beckman Coulter, Inc.
  • 18.10. Bio-Rad Laboratories, Inc.
  • 18.11. BioAgilytix Labs, LLC
  • 18.12. bioMerieux S.A.
  • 18.13. Bristol-Myers Squibb Company
  • 18.14. Eli Lilly and Company
  • 18.15. Exagen, Inc.
  • 18.16. F. Hoffmann-La Roche Ltd.
  • 18.17. GlaxoSmithKline PLC
  • 18.18. Johnson & Johnson Services, Inc.
  • 18.19. Lupin Limited
  • 18.20. Merck & Co., Inc.
  • 18.21. Novartis AG
  • 18.22. Pfizer, Inc.
  • 18.23. Sanofi S.A.
  • 18.24. Siemens Healthineers AG
  • 18.25. Thermo Fisher Scientific Inc.
  • 18.26. Trinity Biotech PLC
  • 18.27. UCB S.A.
  • 18.28. Werfen S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ANTIHYPERGLYCEMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ANTIHYPERGLYCEMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ANTIHYPERGLYCEMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY LUPUS ERYTHEMATOSUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY LUPUS ERYTHEMATOSUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY LUPUS ERYTHEMATOSUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE PROGRESSION ALTERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE PROGRESSION ALTERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE PROGRESSION ALTERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNE SYSTEM MODULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNE SYSTEM MODULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNE SYSTEM MODULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REDUCTION OF INFLAMMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REDUCTION OF INFLAMMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REDUCTION OF INFLAMMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 186. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 188. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 190. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. GCC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 213. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 215. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 216. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 217. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. G7 AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 222. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 224. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 225. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 226. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 229. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. NATO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)